05.06.19
BioDuro, a drug discovery and development services organization, has made four senior leadership appointments, including: David Hedden, chief scientific officer; Brett Truitt, vice president, cGMP operations; Mohan Thiruvazhi, vice president, business development; and Raymond Li, vice president, finance.
“I am truly excited to be part of this exceptional team,” said Cyrus Mirsaidi, president and chief executive officer, BioDuro. “These key additions to the leadership team, augmented by proven track record of our existing executives, supremely positions BioDuro to continue the remarkable growth we have realized over the past 3 years and to fulfill our expectations for our next growth phase, with focus on innovation, quality, and service to our clients, worldwide.”
David Hedden, promoted to chief scientific officer, will be responsible for the scientific leadership and management of the formulation and analytical development teams as well as provide business development technical support. He brings 32 years of pharmaceutical industry experience, most notably with Pfizer, UPM, Ironwood, Searle/Pharmacia, Sandoz, Dupont, and Adagio, with expertise in pharmaceutics, formulation, process development, and manufacturing for small molecules.
Brett Truitt, appointed to vice president, cGMP operations, will provide technical and business leadership for BioDuro’s cGMP operations in its next phase of growth. He has 20 years of experience in diverse pharmaceutical environments from early stage companies to industry leading organizations most notably Flatley Discovery Labs, Shire, Pfizer, and Proctor and Gamble. Most recently, he served as director of pharmaceutics and process technology at Patheon.
Mohan Thiruvazhi, appointed to vice president, business development, brings to BioDuro a blend of scientific and commercial experience from leading pharma and contract research organizations. He will be responsible for global business development efforts in North America, South America, and Europe. He spent a decade at GVK BIO and Syngene International, where he executed U.S. and European strategies to expand geography and client footprints.
Raymond Li, appointed to vice president, finance, brings a wealth of finance and accounting experience to BioDuro, having served in senior positions at publicly traded, fortune 500 companies (K2 and Emerson Electric), augmented by his experience with having completed IPO preparation for biopharma companies. In his last position as vice president of finance and operations for Ambrx, he managed all financial reporting to GAAP and IFRS standards and operationally managed full implementation of a global ERP system.
“I am truly excited to be part of this exceptional team,” said Cyrus Mirsaidi, president and chief executive officer, BioDuro. “These key additions to the leadership team, augmented by proven track record of our existing executives, supremely positions BioDuro to continue the remarkable growth we have realized over the past 3 years and to fulfill our expectations for our next growth phase, with focus on innovation, quality, and service to our clients, worldwide.”
David Hedden, promoted to chief scientific officer, will be responsible for the scientific leadership and management of the formulation and analytical development teams as well as provide business development technical support. He brings 32 years of pharmaceutical industry experience, most notably with Pfizer, UPM, Ironwood, Searle/Pharmacia, Sandoz, Dupont, and Adagio, with expertise in pharmaceutics, formulation, process development, and manufacturing for small molecules.
Brett Truitt, appointed to vice president, cGMP operations, will provide technical and business leadership for BioDuro’s cGMP operations in its next phase of growth. He has 20 years of experience in diverse pharmaceutical environments from early stage companies to industry leading organizations most notably Flatley Discovery Labs, Shire, Pfizer, and Proctor and Gamble. Most recently, he served as director of pharmaceutics and process technology at Patheon.
Mohan Thiruvazhi, appointed to vice president, business development, brings to BioDuro a blend of scientific and commercial experience from leading pharma and contract research organizations. He will be responsible for global business development efforts in North America, South America, and Europe. He spent a decade at GVK BIO and Syngene International, where he executed U.S. and European strategies to expand geography and client footprints.
Raymond Li, appointed to vice president, finance, brings a wealth of finance and accounting experience to BioDuro, having served in senior positions at publicly traded, fortune 500 companies (K2 and Emerson Electric), augmented by his experience with having completed IPO preparation for biopharma companies. In his last position as vice president of finance and operations for Ambrx, he managed all financial reporting to GAAP and IFRS standards and operationally managed full implementation of a global ERP system.
